Abstract
Idiopathic unconjugated hyperbilirubinemia (Gilberts syndrome, GS) is a relatively common congenital hyperbilirubinemia occurring in 3-7% of the world population. It has been recognized as a benign familial condition in which hyperbilirubinemia occurs in the absence of structural liver disease or hemolysis, and the plasma concentration of conjugated bilirubin is normal. Recently, it was reported that uncojugated bilirubin had neurotoxicity in the developing nervous system. The ‘neurodevelopmental hypothesis’ of schizophrenia was proposes that a yet-unidentified event occurring in utero or early postnatal life. We have observed that patients suffering from schizophrenia frequently present an increased unconjugated bilirubin plasma concentration when admitted to the hospital. Therefore, we had notice the relation between unconjugated bilirubin and the etiology and vulnerability of schizophrenia. Our reported findings suggest that there are significant biological and clinical character differences between schizophrenic patients with GS and without GS. From the viewpoint of heterogeneity of schizophrenia, there may be poor outcome for the subtype of schizophrenia with GS.
Keywords: Schizophrenia, (Gilbert's Syndrome), Hyperbilirubinemia, liver disease, neurodevelopmental hypothesis, etiology, heterogeneity
Central Nervous System Agents in Medicinal Chemistry
Title: Schizophrenia and Idiopathic Unconjugated Hyperbilirubinemia (Gilberts Syndrome)
Volume: 8 Issue: 4
Author(s): Tsuyoshi Miyaoka, Rei Wake, Maiko Hayashida and Jun Horiguchi
Affiliation:
Keywords: Schizophrenia, (Gilbert's Syndrome), Hyperbilirubinemia, liver disease, neurodevelopmental hypothesis, etiology, heterogeneity
Abstract: Idiopathic unconjugated hyperbilirubinemia (Gilberts syndrome, GS) is a relatively common congenital hyperbilirubinemia occurring in 3-7% of the world population. It has been recognized as a benign familial condition in which hyperbilirubinemia occurs in the absence of structural liver disease or hemolysis, and the plasma concentration of conjugated bilirubin is normal. Recently, it was reported that uncojugated bilirubin had neurotoxicity in the developing nervous system. The ‘neurodevelopmental hypothesis’ of schizophrenia was proposes that a yet-unidentified event occurring in utero or early postnatal life. We have observed that patients suffering from schizophrenia frequently present an increased unconjugated bilirubin plasma concentration when admitted to the hospital. Therefore, we had notice the relation between unconjugated bilirubin and the etiology and vulnerability of schizophrenia. Our reported findings suggest that there are significant biological and clinical character differences between schizophrenic patients with GS and without GS. From the viewpoint of heterogeneity of schizophrenia, there may be poor outcome for the subtype of schizophrenia with GS.
Export Options
About this article
Cite this article as:
Miyaoka Tsuyoshi, Wake Rei, Hayashida Maiko and Horiguchi Jun, Schizophrenia and Idiopathic Unconjugated Hyperbilirubinemia (Gilberts Syndrome), Central Nervous System Agents in Medicinal Chemistry 2008; 8 (4) . https://dx.doi.org/10.2174/187152408786848111
DOI https://dx.doi.org/10.2174/187152408786848111 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Pathogenesis of Neurotrauma Indicates Targets for Neuroprotective Therapies
Current Neuropharmacology Signaling Pathways that Regulate Basal ABC Transporter Activity at the Blood- Brain Barrier
Current Pharmaceutical Design A Review on Deep Learning Architecture and Methods for MRI Brain Tumour Segmentation
Current Medical Imaging Ischemic and Oxidative Damage to the Hypothalamus May Be Responsible for Heat Stroke
Current Neuropharmacology Signaling Pathways Involved in Neuron-Astrocyte Adhesion and Migration
Current Molecular Medicine Ultrasound Imaging of Muscle-tendon Architecture in Neurological Disease: Theoretical Basis and Clinical Applications
Current Medical Imaging Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Editorial [Hot Topic: Cyclooxygenases and Cyclooxygenase Inhibitors in Neurological and Psychiatric Diseases (Executive Editor: Luisa Minghetti) ]
Current Pharmaceutical Design A Review on Expedient Assets of Polymers Employed in Novel Topical Formulation for Successful Treatment of Arthritis
Current Applied Polymer Science Acid Sensing Ion Channels and Acid Nociception
Current Pharmaceutical Design Structure-Based Design, Synthesis and Molecular Modeling Studies of Thiazolyl Urea Derivatives as Novel Anti-Parkinsonian Agents
Medicinal Chemistry The Effect of SEX/Gender on Cardiovascular Pharmacology
Current Pharmaceutical Design Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Current Pharmaceutical Design Protein-Energy Malnutrition Alters Hippocampal Plasticity-Associated Protein Expression following Global Ischemia in the Gerbil
Current Neurovascular Research Alzheimer’s Disease-like Early-phase Brain Pathogenesis: Self-curing Amelioration of Neurodegeneration from Pro-inflammatory ‘Wounding’ to Anti-inflammatory ‘Healing’
Current Alzheimer Research The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimers Disease
Current Genomics In vivo Proton Magnetic Resonance Spectroscopy and its Applications in Autistic Disorder
Current Molecular Imaging (Discontinued) Anticonvulsant and Antinociceptive Actions of Novel Adenosine Kinase Inhibitors
Current Topics in Medicinal Chemistry Calcium Metabolism and Oxidative Stress in Bone Fractures: Role of Antioxidants
Current Drug Metabolism Neuroprotection in Hypoxic-Ischemic Brain Injury Targeting Glial Cells
Current Pharmaceutical Design